Please login to the form below

Not currently logged in
Email:
Password:

Genzyme agrees thyroid cancer diagnostic deal with Veracyte

Sanofi-owned biotech to complement genomic diagnostic tool with its own Thyrogen product

Genzyme has signed a global co-promotional deal for a genomic diagnostic tool from molecular diagnostics company Veracyte.

The biotech, which is owned by Sanofi, will market and promote Veracyte's technology for improved thyroid nodule diagnosis in the US, with subsequent plans to cover the rest of the world.

Current methods of thyroid cancer diagnosis involving fine needle aspirations (FNAs) produce ambiguous results in up to 30 per cent of cases, according to Genzyme, with the results providing hard to interpret.

Veracyte's tool, called Afirma Thyroid FNA Analysis, aims to improve diagnostic capabilities in thyroid cancer by combining assessment of thyroid nodule FNA samples at a cellular level with a genomic test that can help clarify whether thyroid nodules are benign or potentially dangerous. 

Financial terms of the agreement were not disclosed, but Genzyme plans to use Veracyte's diagnostic capabilities alongside its own Thyrogen (thyrotropin alfa for injection). This is approved for use as an adjunctive diagnostic tool for well-differentiated thyroid cancer by testing for the hormone thyroglobulin.

It is hoped that superior diagnosis techniques will lead to a significant reduction the number of unnecessary thyroid removals, with post-surgery results suggesting that only 20 - 30 per cent of patients who have their thyroids removed have cancer.

“This partnership is a strong fit for both companies and underscores Genzyme's commitment to improving the quality of care for patients with suspected or diagnosed thyroid cancer,” said Genzyme's head of rare diseases, Dr Rogerio Vivaldi.

“Together, our products offer patients and physicians a powerful personalised medicine solution for the diagnosis and treatment of thyroid cancer, addressing an unmet need in the community and improving patient outcomes.”

It is estimated that there will be over 50,000 new cases of thyroid cancer in the US during 2012, with such a rate of incidents of the disease making it the fastest growing cancer in the country.

24th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics